SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 3 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.

Recs

0
Player Avatar turingmouse (67.81) Submitted: 12/26/2006 9:36:56 AM : Outperform Start Price: $3.23 SCLN Score: +79.43

good cancer trials

Report this Post Reply

Featured Broker Partners


Advertisement